NCT06068179 Graves' Disease Remission Study: MycoMeth Combo
| NCT ID | NCT06068179 |
| Status | Recruiting |
| Phase | Phase 2, Phase 3 |
| Sponsor | The First Affiliated Hospital of Xiamen University |
| Condition | Graves' Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 205 participants |
| Start Date | 2023-10-16 |
| Primary Completion | 2025-10-08 |
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
A randomized study to evaluate the efficacy and safety of combining mycophenolate mofetil with methimazole in patients with newly diagnosed Graves' disease.
Eligibility Criteria
Inclusion Criteria: \- 1. aged 18 to 60 years. 2\. Patients newly diagnosed with Graves' disease. Exclusion Criteria: * 1\. Patients with Graves' disease who have undergone treatment or experienced relapse. 2\. Hyperthyroidism due to other etiologies (toxic multinodular goiter, toxic thyroid adenoma, Hashimoto's thyroiditis, subacute thyroiditis, iodine-induced hyperthyroidism, etc.). 3\. Individuals requiring intervention for moderate to severe thyroid eye disease at the time of enrollment. 4\. Patients with hyperthyroidism requiring surgery due to concurrent thyroid cancer. 5\. Those with severe liver or kidney dysfunction (ALT or AST \> 3 times the upper limit of normal reference values, blood creatinine \> 135 mol/L for males, and 110 mol/L for females). 6\. Individuals with leukopenia (WBC \< 3.0×109/L). 7\. Patients with severe heart failure (NYHA class III or IV). 8\. Individuals with chronic or severe infections such as pulmonary tuberculosis, hepatitis B, etc. 9\. Pregnant wom